DFP-10917
CAS No. 135598-68-4
DFP-10917( CNDAC | TAS-109 )
Catalog No. M11458 CAS No. 135598-68-4
DFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameDFP-10917
-
NoteResearch use only, not for human use.
-
Brief DescriptionDFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells.
-
DescriptionDFP-10917 (CNDAC, TAS-109) is a deoxycytidine analog with antitumor activity against various tumor cells; is an orally available nucleoside analog prodrug of CNDAC, CNDAC (DFP-10917) is phosphorylated to generate its nucleotide form, functioning as a deoxycytosine mimic and is incorporated into DNA in tumor cells, causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, resulting in G2/M phase-arrest and tumor cell apoptosis.Blood Cancer Phase 2 Clinical.
-
In VitroCell Viability Assay Cell Line:Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF CHO cellsConcentration:0-1 μMIncubation Time:24 hResult:Inhibited cell survival with IC50s of 0.006, 0.32, 0.48 and 0.0053 μM against Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF cell lines, respectively.Cell Proliferation Assay Cell Line:HL-60 and THP-1 cells Concentration:0-100 μM Incubation Time:3 days Result:Inhibited proliferation with IC50s of 1.5832 μM and 0.84 μM against HL-60 and THP-1 cells, respectively.Apoptosis Analysis Cell Line:HL-60 and THP-1 cells Concentration:0, 0.5, 1, 2, 3, 4, 5 and 10 μM Incubation Time:3, 4, 5, and 6 days Result:Induced apoptosis in both cells.Cell Cycle Analysis Cell Line:HCT116 Concentration:6?μM Incubation Time:48?h Result:36 and 36% of cells were arrested in late-S and G2/M phases, respectively.
-
In VivoAnimal Model:CDF1 mice, P388 tumor modelDosage:20 mg/kg Administration:Intraperitoneal injection, daily for 10 daysResult:Greatly increased the survival time and survival rate.
-
SynonymsCNDAC | TAS-109
-
PathwayCell Cycle/DNA Damage
-
TargetNucleoside Antimetabolite/Analog
-
RecptorNucleoside Antimetabolite/Analog
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number135598-68-4
-
Formula Weight252.23
-
Molecular FormulaC10H12N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#C[C@@H]1[C@H](N2C=CC(N)=NC2=O)O[C@H](CO)[C@H]1O
-
Chemical Name(2R,3S,4S,5R)-2-(4-amino-2-oxopyrimidin-1(2H)-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-carbonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Matsuda A, et al. J Med Chem. 1991 Sep;34(9):2917-9.
2. Sankhala K, et al. Invest New Drugs. 2018 Apr 18. doi: 10.1007/s10637-018-0602-0.
3. Hanaoka K, et al. Int J Cancer. 1999 Jul 19;82(2):226-36.
4. Tanaka M, et al. Cancer Lett. 1992 May 30;64(1):67-74.
molnova catalog
related products
-
Tipiracil hydrochlor...
Tipiralacil, also known as TPI, is a thymidine phosphorylase inhibitor (TPI).
-
Elacytarabine
Elacytarabine (CP-4055, CP4055, ELACYT) is a fatty acid derivative of cytarabine with potential antineoplastic activity.
-
Acelarin
A gemcitabine phosphoramidate prodrug that can overcome the key cancer resistance.
Cart
sales@molnova.com